What Is HER2-Negative Breast Cancer?

What is described here is the most prevalent form of breast cancer, HER2-negative, a designation that directly informs how clinicians approach diagnosis, risk assessment, and the choice of therapies. HER2 is a receptor on the surface of breast cells, and when levels are very high, cancers become HER2-positive, whereas HER2-negative tumors have little or no HER2 protein present. Testing for HER2 helps define critical aspects of the illness that shape treatment plans because certain targeted therapies work only against HER2-positive tumors and would be ineffective against HER2-negative disease. HER2-negative breast cancer represents about 78% of all cases, and its signs can resemble other problems of the breast, so early evaluation is crucial for proper management.

The article identifies two HER2-negative subtypes defined by hormone receptor status: HER2-negative, HR-positive, which accounts for about 68% of female breast cancer cases. The other subtype, HER2-negative, HR-negative, is commonly referred to as triple-negative and represents about 10% and lacks both hormone receptors along with HER2 expression. These distinctions guide therapeutic options, as HR-positive cancers may respond to endocrine therapy, while triple-negative cancers currently lack targeted HER2 or hormonal targets. Although the causes remain not fully defined, genetics, lifestyle, and environmental factors are believed to contribute to risk, underscoring the need for personalized screening and management.